Beta
45306

Alagebrium and spironolactone ameliorate dietary induced metabolic syndrome in male Wister rats

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Clinical Pharmacology

Abstract

Background: Metabolic syndrome (MS) is associated with chronic hyperglycemia, which leads to formation of advanced glycation end products (AGEs) that involved in the disease pathogenesis. MS is also accompanied by mineralocorticoid receptor (MR) activation, which has deleterious metabolic effects. The present study was designed to compare the effect of alagebrium (ALA), standard AGEs cross link breaker, and spironolactone (SPL), MR antagonist, on MS induced by high carbohydrate and high fat diet (HCFD).
Methods: 32 rats divided into: normal control group (8 rats) fed standard diet, and MS group (24 rats) received HCFD for 10 weeks, after which they were divided into 3 equal subgroups and continued on HCFD for further 6 weeks and served as: MS control, ALA treated (10 mg/kg/day), and SPL treated (50 mg/kg/day). Studied parameters were mean arterial blood pressure (MABP), body weight (BW), fasting blood glucose (FBG), serum insulin, HbA1c, plasma lipids, liver enzymes, oxidative stress & inflammatory markers, and liver histopathology.
Results: HCFD produced MS as evidenced by significant deleterious effect on all parameters, and treatment with either ALA or SPL produced significant favorable effect on these parameters. In comparison, ALA was superior in decreasing FBG, HbA1c, serum TGs, ALT, GGT and hepatic inflammatory markers. SPL was superior in decreasing MABP, BW, serum insulin, LDL, and antioxidant status.
Conclusion: ALA and SPL showed protective effect on dietary induced MS, both could be promising in management of the disease.
Keywords: Alagebrium, Spironolactone, metabolic syndrome.

DOI

10.21608/zumj.2019.15694.1406

Keywords

Alagebrium, Spironolactone, Metabolic syndrome

Authors

First Name

Seba

Last Name

Hassan

MiddleName

-

Affiliation

Clinical pharmacology department,Faculty of medicine,Zagazig university,Egypt

Email

seba_hassan@yahoo.com

City

Zagazig

Orcid

-

First Name

Ali

Last Name

Moustafa

MiddleName

Abdelrahman

Affiliation

Clinical pharmacology department, Faculty of Medicine, Zagazig University, Egypt

Email

dr.alypharma48@gmail.com

City

Zagazig

Orcid

-

First Name

Soad

Last Name

Kabil

MiddleName

Lotfy

Affiliation

Pharmacology Department, Faculty of Medicine, Zagazig University, Egypt

Email

soadkabil2004@gmail.com

City

-

Orcid

-

First Name

Nevertyty

Last Name

Mahmoud

MiddleName

Mohamed

Affiliation

Clinical pharmacology department, Faculty of Medicine, Zagazig University, Egypt

Email

nevertytymohamed@yahoo.com

City

-

Orcid

-

Volume

27

Article Issue

2

Related Issue

22498

Issue Date

2021-03-01

Receive Date

2019-08-06

Publish Date

2021-03-01

Page Start

324

Page End

333

Print ISSN

1110-1431

Online ISSN

2357-0717

Link

https://zumj.journals.ekb.eg/article_45306.html

Detail API

https://zumj.journals.ekb.eg/service?article_code=45306

Order

193

Type

Original Article

Type Code

273

Publication Type

Journal

Publication Title

Zagazig University Medical Journal

Publication Link

https://zumj.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023